TIKOSYN Site Map
- Healthcare Professionals
- Hospitals
- Retail Pharmacists
- Patients
- Patient Brochure - English
- Patient Brochure - Spanish
- Patient Letter – English
- Patient Letter – Spanish
- Patient Quick Check List – English
- Patient Quick Check List – Spanish
- Patient Information Card – English
- Patient Information Card – Spanish
- Pfizer Helpful Answers
- Tikosyn (dofetilide) Patient Product Information - English
- Tikosyn (dofetilide) Patient Product Information - Spanish
- Patient Frequently Asked Questions (FAQs)
- Frequently Asked Questions (FAQs)
TIKOSYN is indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm.
TIKOSYN is indicated for the conversion of atrial fibrillation/atrial flutter to normal sinus rhythm.
TIKOSYN is indicated for the conversion of atrial fibrillation/atrial flutter to normal sinus rhythm.
To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation (for detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION). TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education (see DOSAGE AND ADMINISTRATION). For full Prescribing information, please click here.
The product information in this site is intended for residents of the United States only.